Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer

Nicosia, Cyprus, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that one of the acquisition companies of the previously-announced Biocogency merger, Bebig LLC (http://en.bebig.ru), received an updated Russian registration certificate for the production and sale of nanostructured microspheres based on yttrium-90, used in the treatment of both primary and metastatic liver lesions. This will start industrial production and sale of ready-made batches of microspheres to medical institutions for use in radiotherapy of primary and metastatic liver tumors. This technology is recognized as the most effective for treating inoperable patients with liver cancer. In total, three companies in the world own this microsphere production technology: MDS Nordion (Canada), Sirtex (Australia), and now Bebig LLC (Russia).

Read the original here:
Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer

Related Post